Editorial: Central & Peripheral Nervous Systems: Cannabinoid receptor ligands: clinical and neuropharmacological considerations relevant to future drug discovery and development

References

• PERT WEE R: Pharmacology of cannabinoid CBi and CB2 receptors. Pharmacol. Ther (1996). In press. A detailed review of the pharmacology of cannabinoid CBI and CB2 receptors.
   Google Scholar
• PERTWEE RG: Pharmacological, physiological and dial- cal implications of the discovery of cannabinoid recep-tors: an overview. In: Cannabinoid Receptors. Pertwee RG (Ed.), Academic Press, London (1995):1–34. Contributors to this book have played crucial roles in major recent advances in cannabinoid pharmacology.
   Google Scholar
• PERT WEE R: The evidence for the existence of cannabi-noid receptors. Gen. Pharmacol. (1993) 24(4):811–824.
   PubMedGoogle Scholar
• SHIRE D, CARILLON C, KAGHAD M et al.: An amino-ter-minal variant of the central cannabinoid receptor re-sulting from alternative splicing. J. Biol. Chem. (1995) 270(8):3726–3731.
   PubMed Web of Science ®Google Scholar
• GALIEGUE S, MARY S, MARCHAND J et al.: Expression of central and peripheral cannabinoid receptors in hu-man immune tissues and leukocyte subpopulations. Eur. J. Biochem. (1995) 232(1):54–61. A detailed account of the distribution of CBI and CB2 mRNA in peripheral tissues.
   Google Scholar
• HERICENHAM M: Localization of cannabinoid receptors in brain and periphery. In: Cannabinoid Receptors. Pert-wee RG (Ed.), Academic Press, London (1995):145–166. Contributors to this book have played crucial roles in major recent advances in cannabinoid pharmacology.
   Google Scholar
• HOLSAPPLE MP, KARRAS JG, LEDBETTER JA etal.: Molecu-lar mechanisms of toxicant-induced immunosuppres- sion: role of second messengers. Ann. Rev. Pharmacol. Taxicol. (1996) 36:131–159.
   Google Scholar
• FACCI L, DAL TOSO R, ROMANELLO S et al.: Mast cells express a peripheral cannabinoid receptor with differ- ential sensitivity to anandamide and pahnitoylethano- lamide. Proc. Natl. Acad. Sci. USA (1995) 92(8):3376–3380. Contains evidence that cannabinoids can prevent mast cell degranu-lation.
   Google Scholar
• MARTIN BR, THOMAS BF, RAZDAN RK: Structural require- ments for cannabinoid receptor probes. In: Cannabi-noid Receptors. Pertwee RG (Ed.), Academic Press, London (1995):35–85. Contributors to this book have played crucial roles in major recent advances in cannabinoid pharmacology.
   Google Scholar
• HUFFMAN JW, LAINTON JAH: Recent developments in the medicinal chemistry of cannabinoids. Curr. Med. Chem. (1996) 3:101-116. A recent review of cannabinoid structure-activity relationships.
   Google Scholar
• SHOWALTER VM, COMPTON DR, MARTIN BR, ABOOD ME: •Evaluation of binding in a transfected cell line express- ing a peripheral cannabinoid receptor (CB2): identifi-cation of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Then (1996). In press. Contains important data about the degree of CBI- and CB2 -selectivity shown by a range of established and novel cannabinoid receptor ligands.
   Google Scholar
• HUFFMAN JW, YU S, SHOWALTER V et al.: Synthesis and •pharmacology of a very potent cannabinoid larking aphenolic hydroxyl with high affinity for the CB2 recep-tor. J. Med. Chem. (1996). In press. Contains important data about the degree of CB2-selectivity shown by some established and novel cannabinoid receptor ligands.
   Google Scholar
• GAREAU Y, DUFRESNE C, GALLANT M et al.: Structure •activity relationships of tetrahydrocannabinol ana-logues on human cannabinoid receptors. Bioorg. Med. Chem. Lett. (1996) 6(2):189–194. Contains important data about the degree of CB2-selectivity shown by some novel cannabinoid receptor ligands.
   Google Scholar
• FELDER CC, JOYCE RE, BRILEY EM etal.: Comparison of the pharmacology and signal transduction of the hu-man cannabinoid Cilit and CB2 receptors. Mol. Pharma-col. (1995) 48(3):443–450. Contains data about the degree of CI31- and CB2-selectivity shown by a range of established cannabinoid receptor ligands.
   Google Scholar
• BAYEWITCH M, AVIDOR-REISS T, LEVY R et al.: The peripheral cannabinoid receptor: adenylate cycLase in-hibition and G protein coupling. FESS Lett. (1995) 373(1-2):143–147.
   Web of Science ®Google Scholar
• BAYEWITCH M, RHEE M-H, AVIDOR-REISS T etal.: (-)-A9- tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cydase. J. Biol. Chem. (1996) 271(17):9902–9905. Evidence that A9-tetrahydrocannabinol has affinity for CB2 receptors but little CB2 efficacy.
   Google Scholar
• BOUABOULA M, POINOT-CHAZEL C, MARCHAND J etal.: Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both raitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. (1996) 237(3):704–711.
   Google Scholar
• SLIPETZ DM, O'NEILL GP, FAVREAU L etal.: Activation ofthe human peripheral cannabinoid receptor results in Inhibition of adenyly1 cyclase. Mol. Pharmacol. (1995) 48(2):352–361.
   Google Scholar
• FAHEY K, CHANEY M, CULLINAN G et al.: The synthesis •and biological activity of a novel class of antagonists forthe brain CB-1 cannabinoid receptor. Soc. Neurosci. Abstracts (1995) 21:1144. First report of a new cannabinoid receptor antagonist (LY320135).
   Google Scholar
• MECHOULAM R, VOGEL Z, BARG Jr CNS cannabinoidreceptors. Role and therapeutic implications for CNS disorders. CNS Drugs (1994) 2(4):255–260.
   Google Scholar
• BASS R, ENGELHARD D, TREMBOVLER V, SHOHAMI E: A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. J. Infect. Dir. (1996) 173(3):735–738.
   PubMed Web of Science ®Google Scholar
• HOLLISTER LE: Health aspects of cannabis. Pharmacol. •Revs. (1986) 38:1-20. Includes an excellent well-balanced review of the therapeutic po-tential of cannabinoids (written before the discovery of cannabinoid receptors).
   Google Scholar
• SONG Z-H, BONNER TI: A lysine residue of the cannabi-noid receptor is critical for receptor recognition by several agonists but not W1N55212-2. Mol. Pharmacol. (1996) 49(5):891–896.
   PubMed Web of Science ®Google Scholar
• DEVANE WA, HANUS L, BREUER A et al.: Isolation and •structure of a brain constituent that binds to thecannabinoid receptor. Science (1992) 258(5090):1946–1949. First report of an endogenous cannabinoid receptor agonist (anan-darnide).
   Google Scholar
• MECHOULAM R, FRIDE E: The unpaved road to the endogenous brain cannabinoid ligands, the anan-damides. In: Cannabinoid Receptors. Pertwee RG (Ed.), Academic Press, London (1995):233–258. Contributors to this book have played crucial roles in major recent advances in cannabinoid pharmacology.
   Google Scholar
• MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identifi- cation of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Bio-chem. Pharmacol. (1995) 50(1):83–90.
   PubMed Web of Science ®Google Scholar
• THOMAS BF, ADAMS IB, MASCARELLA SW, MARTIN BR, RAZDAN RK: Structure-activity analysis of anandamble analogs: relationship to a cannabinoid pharmaco-phore. j Med. Chem. (1996) 39(2):471–479.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, HEAULME M et al.: •SR141716A, a potent and selective antagonist of thebrain cannabinoid receptor. FEBS Lett. (1994) 350(2–3):240-244. First full report of the development of a potent selective CI31 receptor antagonist (SR141716A).
   Google Scholar
• PERTWEE RG, FERNANDO SR, NASH JE, COUTTS AA: Further evidence for the presence of cannabinoid Clii receptors in guinea-pig small intestine. Br.J. Pharmacol. (1996) 118:2199–2205.
   PubMed Web of Science ®Google Scholar
• PACHECO M, CHILDERS SR, ARNOLD R, CASIANO F, WARDSJ: Ambloalkylindoles: actions on specific G-protein-linked receptors. j Pharmacol. Exp. Ther. (1991) 257:170–183.
   PubMed Web of Science ®Google Scholar
• EISSENSTAT MA, BELL MR, D'AMBRA TE et al.: Arninoalky-lindoles: structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. (1995) 38(16):3094–3105.
   Google Scholar
• CASIANO FM, ARNOLD R, HAYCOCK D, KUSTER J, WARDSJ: Putative aminoalkylindoles (AA!) antagonists. NIDA Research Monograph Series (1990) 105:295–296.
   PubMedGoogle Scholar
• PERTWEE R, GRIFFIN G, FERNANDO S et al.: AM630, acompetitive runnahinoid receptor antagonist. Life Sci. (1995) 56(23-24):1949–1955.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG, FERNANDO SR, GRIFFIN G et al.: Agonist- antagonist characterization of 6'-cyanohex-2'-yne-A8- tetrahydrocannabinol in two isolated tissue preparations. Eur j. Pharmacol. (1996). In press. First report of a potent partial agonist for cannabinoid receptors with mixed agonist-antagonist properties.
   Google Scholar
• GLASS M, JOYCE K, FELDER C: Pertussis toxin treatmentunmasks a coupling of the Clii receptor to stimulation of cANIP accumulation. Proc. International Cannabinoid Research Society (1996):69.
   Google Scholar
• BEAL JE, OLSON R, LAUBENSTEIN L et al.: Dronabinol asa treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Manage-ment (1995) 10(2):89–97.
   PubMed Web of Science ®Google Scholar
• MAI LES RD, SHAW LM, EDLING-OWENS J, ENGELMAN K, ELSOHLY MA: Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol. Biochem. Behav. (1993) 44(3):745–747. First report of a method for administering a cannabinoid by rectal suppository.
   Google Scholar
• MATTES RD, ENGELMAN K, SHAW LM, ELSOHLY MA: Cannabinoids and appetite stimulation. Pharmacol. Bio-chem. Behav. (1994) 49(1):187–195. Administration of a cannabinoid by rectal suppository to stimulate appetite.
   Google Scholar
• GLASS M, FAULL ELM, DRAGUNOW M: Loss of cannabi-noid receptors in the substantia nigra in Huntington's disease. Neuroscience (1993) 56(3):523–527.
   PubMed Web of Science ®Google Scholar
• RICHFIELD EK, HERKENHAM M: Selective vulnerability inHuntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. (1994) 36(4):577–584.
   PubMed Web of Science ®Google Scholar
• WESTLAKE TM, HOWLETT AC, BONNER TI, MATSUDA LA,HERKENHAM M- C2on2binoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience (1994) 63(3):637–652.
   PubMed Web of Science ®Google Scholar
• PERIO A, RINALDI-CARMONA M, MARUANI J et al.: Centralmediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav. Pharmacol. (1996) 7(1):65–71.
   PubMed Web of Science ®Google Scholar
• SIM LJ, SELLEY DE, CHILDERS SR: In vitro autoradiogra-phy of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 54y-[35S}thiokriphos-phate binding. Proc. Natl. Acad. Sci. USA (1995) 92(16):7242–7246.
   PubMed Web of Science ®Google Scholar
• DEUTSCH DG, CHIN SA: Enzymatic synthesis and degra- dation of ananciatnide, a cannabinoid receptor agonist. Biochem. Pharmacol. (1993) 46(5):791–796. First report of the enzymatic pathway responsible for the hydrolysis of the endogenous cannabinoid, anandamide, by brain tissue.
   Google Scholar
• DI MARZO V, FONTANA A, CADAS H et at: Formation and inactivation of endogenous cannabinoid anand2mide In central neurons. Nature (1994) 372(6507):686–691. First evidence that neurones contain release and uptake mechanisms for the endogenous cannabinoid, anandatnide.
   Google Scholar
• HILLARD CJ, WILKISON DM, EDGEMOND WS, CAMPBELLWB: Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta (1995) 1257(3):249–256.
   PubMed Web of Science ®Google Scholar
• TERRANOVAR, STORME kJ, LAFON N et al.: Improvementof memory in rodents by the selective CBI cannabinoid receptor antagonist, SR 141716. Psychopharmacology (1996) 126(2):165–172.
   PubMed Web of Science ®Google Scholar